<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695978</url>
  </required_header>
  <id_info>
    <org_study_id>GENA-25</org_study_id>
    <nct_id>NCT03695978</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety &amp; Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated &amp; Minimally Treated Haemophilia A Patients</brief_title>
  <acronym>Protect-NOW</acronym>
  <official_title>Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated &amp; Minimally Treated Haemophilia A Patients Entering Routine Clinical Treatment With Nuwiq, Octanate or Wilate - Efficacy &amp; Safety Observational Study-Protect-NOW</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, post-authorisation non-interventional study to evaluate real-life
      effectiveness, safety and utilisation patterns of Octapharma's FVIII concentrates Nuwiq,
      Octanate, and Wilate in previously untreated and minimally treated severe haemophilia A
      patients in routine clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Octapharma's FVIII concentrates have been tested in clinical trials and registered for
      treatment of haemophilia A; however, as haemophilia A is a rare disease, the numbers of
      patients treated in studies so far are limited. For previously untreated patients (PUPs), who
      are typically young children, and for minimally treated patients (MTPs), who have been
      exposed to only minimal FVIII dosages, there is a general interest to increase the body of
      data on treatment effectiveness and safety, particularly related to inhibitor development.
      Also, specifically for PUPs, treatment algorithms are not standardized, e.g. with respect to
      utilisation, dosage, frequency or optimal start age of FVIII prophylaxis. Real world evidence
      derived from a non-interventional study (NIS) can describe product utilisation and
      demonstrate value over a product's life cycle and facilitate benefit-risk assessments. The
      purpose of this study is thus to evaluate product utilisation, effectiveness and safety,
      including inhibitor development information, in severe haemophilia A PUPs and MTPs, who have
      been prescribed Octapharma's FVIII concentrates.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Annualised rate of breakthrough bleeds to assess efficacy in prophylactic treatment</measure>
    <time_frame>100 exposure days</time_frame>
    <description>Annualised rate of all bleeding events (BEs), including all spontaneous, traumatic and joint BEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Drug Reactions (ADRs)</measure>
    <time_frame>100 exposure days</time_frame>
    <description>Adverse drug reactions (ADRs) including hypersensitivity reactions will be recorded in by patients in treatment diaries, which will be reviewed at each Follow-up Visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosage of FVIII concentrates</measure>
    <time_frame>100 exposure days</time_frame>
    <description>For each individual FVIII injection the dose will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall assessment of the effectiveness of surgical prophylaxis by the treating physicians</measure>
    <time_frame>100 exposure days</time_frame>
    <description>At the end of the postoperative period, treating physicians will assess the effectiveness of surgical prophylaxis using a scale including the four items: 'excellent,' 'good,' moderate,' and 'none'.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Haemophilia A</condition>
  <arm_group>
    <arm_group_label>Nuwiq</arm_group_label>
    <description>All patients receiving Nuwiq (recombinant FVIII)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octanate</arm_group_label>
    <description>All patients receiving Octanate (plasma derived FVIII)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wilate</arm_group_label>
    <description>All patients receiving Wilate (plasma derived FVIII/von Willebrand factor [VWF])</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 140 patients, either previously untreated patients (PUPs) or minimally treated
        patients (MTPs), are planned to be documented in the study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients of any age and ethnicity

          -  Severe haemophilia A (FVIII:C&lt;1%)

          -  Decision to prescribe Octapharma's FVIII concentrate before enrollment into the study

          -  Either

          -  No previous treatment with FVIII concentrates or other blood products containing FVIII
             (PUPs) OR

          -  Less than 5 Exposure Days (EDs) to FVIII concentrates or other blood products
             containing FVIII (MTPs), if

          -  their first ED occurred after 1st January 2015, AND

          -  they did not develop an inhibitor at any time point, OR

          -  they developed an inhibitor during treatment with an Octapharma FVIII concentrate AND
             continue treatment with THIS Octapharma FVIII concentrate

          -  Voluntarily given, fully informed written and signed consent obtained before any
             study-related data documentation is conducted (obtained from the patient's
             parent/legal guardian)

        Exclusion Criteria:

          -  Diagnosis with a coagulation disorder other than haemophilia A

          -  Concomitant treatment with any systemic immunosuppressive drug

          -  Participation in an interventional clinical trial during the time period evaluated

          -  Participation in another non-interventional study of Octapharma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sigurd Knaub, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Octapharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sigurd Knaub, PhD</last_name>
    <phone>+41 554512141</phone>
    <email>Sigurd.Knaub@octapharma.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cure 4 The Kids Foundation Children's Specialty Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Azerbaijan State Advanced Training Institute for Doctors Hematology Department Scientific-Research Center of Hemophilia</name>
      <address>
        <city>Baku</city>
        <zip>AZ1012</zip>
        <country>Azerbaijan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Republican Scientific Center for Radiation Medicine and Human Ecology</name>
      <address>
        <city>Gomel</city>
        <zip>246040</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Romashevskaya</last_name>
      <email>gemd@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Scientific and Practical Centre of Children Oncology, Hematology and Immunology</name>
      <address>
        <city>Minsk</city>
        <zip>223053</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Alenjnikowa</last_name>
      <email>aleinikova2004@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire des Enfants Reine Fabiola</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Phu Quac Le</last_name>
      <email>Phuquoc.LE@huderf.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>An Van Damme</last_name>
      <email>an.vandamme@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McMaster University, Division of Pediatric Hematology/Oncology Room 3N27</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>1800NOCLOTS</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony K.C Chan</last_name>
      <email>akchan@mcmaster.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Hematology Research Research Transition Facility</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Belletrutti</last_name>
      <email>Mark.Belletrutti@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tallinn Childrenś Hospital Clinic of Paediatric Department of Haematology and Oncology</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kadri Saks</last_name>
      <email>kadri.saks@lastehaigla.ee</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Simone Veil Groupement Hospitalier Eaubonne-Montmorency</name>
      <address>
        <city>Montmorency</city>
        <zip>95160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassoun Abel</last_name>
      <email>abel.hassoun@ch-simoneveil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hotel Dieu, Centre de Traitment de l'Hemophilie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Fouassier</last_name>
      <email>marc.fouassier@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Nord, Secretariat de pediatre</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Berger</last_name>
      <email>claire.berger@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes - Netzwerk für Gesundheit GmbH Klinikum im Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Klamroth</last_name>
      <email>Robert.klamroth@vivantes.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Experimental Haematology and Transfusion Medicine (IHT) University Clinic Bonn (AöR)</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Oldenburg</last_name>
      <email>Johannes.Oldenburg@ukb.uni-bonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coagulation Research Centre GmbH</name>
      <address>
        <city>Duisburg</city>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Halimeh</last_name>
      <email>susan.halimeh@gzrr.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lelia Validre</last_name>
      <email>lelia.valdre@aosp.bo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giacomo</name>
      <address>
        <city>Castelfranco Veneto</city>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Radossi</last_name>
      <email>paolo.radossi@aulss2.veneto@it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giancarlo Castaman</last_name>
      <email>giancarlo.castaman@unifi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>920122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Santangostino</last_name>
      <email>elena.santagostino@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Emofilia - AUO di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Chistolini</last_name>
      <email>antonio.chistolini@uniroma1.it</email>
    </contact>
    <contact_backup>
      <email>chistolini@bce.uniroma1.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ospedale Regina Margherita</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berardino Pollio</last_name>
      <email>bpollio@cittadellasalute.to.it</email>
    </contact>
    <contact_backup>
      <email>berardino.pollio@hotmail.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Affiliate of Vilnius Universtity Hospital Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonata Saulyte Trakymiene</last_name>
      <email>sonata.trakymiene@vuvl.lt</email>
    </contact>
    <contact_backup>
      <email>sonatrak@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Moscow State Government-financed Public Healthcare Institution &quot;Morozovskaya Children Clinical Hospital of Moscow Healthcare Department&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Petrov</last_name>
      <email>pretrovhemcentr@yandrex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budget Healthcare Institution &quot;City Out-patient Clinical # 37&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Andreeva</last_name>
      <email>spbhemophilia@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante Hematología y Hemoterapia</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascual Marco Vera</last_name>
      <email>marco.pas@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebrón, Unitat d'Hemofilia</name>
      <address>
        <city>Barcelona</city>
        <zip>02035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Benitez Hidalgo</last_name>
      <email>25600173t@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul University Faculty of Medicine</name>
      <address>
        <city>Fatih</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital, Oxford University Hospitals, NHS Foundation Trust</name>
      <address>
        <city>Headington</city>
        <state>Oxford</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neha Bhatnagar</last_name>
      <email>Neha.Bhatnagar@ouh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Georgina Hall</last_name>
      <email>georgina.hall@peadiatrics.ox.ac.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B46NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jayashree Motwani</last_name>
      <email>jayashree.motwani@nhs.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Trust, Haemophilia Centre</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raina Liesner</last_name>
      <email>Ri.Liesner@gosh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newcastle Haemophilia Comprehensive Care Centre, Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tina Biss</last_name>
      <email>Tina.Biss@nuth.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Azerbaijan</country>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

